Q1 EPS Estimate for Axsome Therapeutics Decreased by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities researchers at William Blair dropped their Q1 2025 earnings per share estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Tuesday, April 1st. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($1.49) for the quarter, down from their previous estimate of ($1.46). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. William Blair also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.31) EPS, Q3 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($4.36) EPS, Q1 2026 earnings at ($0.44) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at $0.47 EPS, Q4 2026 earnings at $1.13 EPS, FY2026 earnings at $1.10 EPS, FY2027 earnings at $12.30 EPS, FY2028 earnings at $25.02 EPS and FY2029 earnings at $38.11 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.01. The firm had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%.

Other analysts have also issued research reports about the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $153.00 target price on shares of Axsome Therapeutics in a report on Tuesday, April 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $153.00 price objective on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. Wells Fargo & Company increased their target price on Axsome Therapeutics from $140.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Leerink Partners boosted their target price on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, February 10th. Finally, Bank of America upped their price target on Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $167.64.

Axsome Therapeutics Trading Down 8.4 %

AXSM opened at $98.86 on Friday. The firm has a 50 day simple moving average of $120.62 and a 200 day simple moving average of $101.75. Axsome Therapeutics has a fifty-two week low of $64.11 and a fifty-two week high of $139.13. The company has a market cap of $4.82 billion, a price-to-earnings ratio of -16.50 and a beta of 0.88. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04.

Insider Activity

In other news, CFO Nick Pizzie sold 3,000 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 22.40% of the company’s stock.

Institutional Investors Weigh In On Axsome Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of AXSM. 111 Capital bought a new position in shares of Axsome Therapeutics during the 4th quarter worth approximately $278,000. TFG Asset Management GP Ltd bought a new position in Axsome Therapeutics in the fourth quarter valued at $3,490,000. GF Fund Management CO. LTD. bought a new position in Axsome Therapeutics in the fourth quarter valued at $86,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new stake in Axsome Therapeutics in the 4th quarter valued at $2,853,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Axsome Therapeutics by 20.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,642 shares of the company’s stock worth $4,877,000 after buying an additional 9,928 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.